[ET Net News Agency, 26 September 2019] CSPC Pharmaceutical Group Limited (01093) said
"Metformin Hydrochloride Extended-Release Tablets (0.75g, 0.5g)" developed by its
subsidiary CSPC Ouyi Pharmaceutical Co., Ltd has been granted drug registration approval
by the National Medical Products Administration of the People's Republic of China. Both
dose strengths are deemed to have passed the Consistency of Quality and Efficacy
Evaluation for Generic Drugs, while the 0.75g dose strength is an exclusive product in
China.
Metformin is a hypoglycemic agent which is mainly used to improve glucose tolerance of
type 2 diabetic patients, lowering not only basal blood glucose but also postprandial
blood glucose.
Also, "Glutathione for Injection (0.3g)" developed by its subsidiary CSPC Ouyi
Pharmaceutical Co. Ltd. has been granted drug registration approval by the National
Medical Products Administration of the People's Republic of China.
Glutathione facilitates the metabolism of carbohydrate, fat and protein, and also
facilitates the formation of easy-metabolized compounds of low toxicity, having a
detoxification effect on certain exogenous toxic substances. It can be used for patients
undergoing chemotherapy or radiotherapy, hypoxemia, liver diseases, adjuvant treatment for
organophosphorus or nitro compound intoxication, and drug detoxification. (RC)